
Jan 8 (Reuters) - ProQR Therapeutics NV PRQR.O:
PROQR ANNOUNCES ENCOURAGING AX-0810 PHASE 1 SAFETY AND PK DATA, DEVELOPMENT CANDIDATE SELECTIONS, AND 2026 OUTLOOK
PROQR THERAPEUTICS NV: INITIAL AX-0810 DATA SHOW NO SAFETY SIGNALS AFTER 4 WEEKS OF DOSING AND PHARMACOKINETICS CONSISTENT WITH NON-CLINICAL DATA
PROQR THERAPEUTICS NV: PHASE 1 AX-0810 DATA EXPECTED IN H1 2026